LAWRENCE, Mass., March 29, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and commercialization of novel treatments for diabetes and its related complications, is pleased to announce the addition of two more accomplished and renowned scientists and clinicians to their Scientific Advisory Board. The Company is actively pursuing the path to approval for technology and treatment options that address the neglected areas of unmet medical need that are coming to light as new digital continuous glucose monitoring becomes more widely adopted. BTI-320 and SUGARDOWN are non-systemic treatment alternatives for metabolic disorders whose effect can be readily seen on a meal by meal basis. The additions of Dr. Parnes, a renowned NY physician and a strong supporter of SUGARDOWN®, and Dr. Silverman, an FDA and Regulatory Strategist, round out the expertise of the new Scientific Advisory Board enabling the Company to launch new strategic initiatives in 2018. Full biographical information can be found at https://www.bostonti.com/about-bti/advisors.html
Harold S. Parnes, MD, FACR is a strong supporter of SUGARDOWN non-systemic treatment for glucose intolerance, valuing it as an alterative to other treatments that can lead to hypoglycemia if not managed properly. He is currently Chairman of the Board of Trustees, Alumni Association College of Medicine, State University of NY, Downstate Medical Center, Former Director of Neuroradiology, Dept of Radiology, Queens Hospital Center, and President and Medical Director of Omega Diagnostic Imaging. Dr. Parnes adds important expertise to our understanding of how metabolic defects of diabetes affects neurobiology. As the Company explores new therapeutic opportunities in the area of oxygen perfusion and neurobiology, Dr. Parnes will be an invaluable resource.
Robert Silverman, MD, FACE has helped gain FDA approval for a long list of therapeutic candidates. A Former Merck Research Laboratories (MRL) Executive Director of Global Regulatory Strategy, Policy and Safety, Former NIH, Chief, Diabetes Programs Branch, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, and Former Scientific Officer of the seminal Diabetes Control and Complications Trial (DCCT), Dr. Silverman is an expert in FDA regulatory strategies. As the Company continues to reach clinical milestones and achieve commercialization, Dr. Silverman’s experience will help the team to most efficiently navigate the regulatory process.
Boston Therapeutics, COO, Loraine Upham remarks, “We are honored and thrilled to have these extraordinary global experts to call on for valuable insight and guidance as we drive our products to worldwide commercialization. Dr. Parnes and Dr. Silverman will truly add new dimensions to our newly established team which includes already, Dr. Richard Pittner, Dr. John Amatruda and Dr. Makarand Jawadekar.” The scientific advisory board will convene quarterly and operate through electronic communications as needed.
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.
Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.